Results 101 to 110 of about 25,866 (210)

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Brennan, Cameron W., Campos, Carl, Clark, Owen, Codega, Paolo, DeAngelis, Lisa M., Dogan, Ahmet, Gavrilovic, Igor T., Glass, Jon, Graeber, Thomas G., Grommes, Christian, Gutin, Philip H., Hamlin, Paul, Hatzoglou, Vaios, Hsieh, Wan-Ying, Huse, Jason T., Kaley, Thomas J., Lallana, Enrico C., Mellinghoff, Ingo K., Moskowitz, Craig H., Nichol, Donna, Nolan, Craig P., Noy, Ariela, Omuro, Antonio, Palaskas, Nicolaos, Palomba, M. Lia, Panageas, Katherine S., Pastore, Alessandro, Peak, Scott, Pentsova, Elena, Reiner, Anne S., Rohle, Dan, Rosenblum, Marc, Sauter, Craig S., Schartz, Derrek, Schultz, Nikolaus, Tabar, Viviane S., Tang, Sarah S., Thomas, Alissa A., Tsyvkin, Elina, Viale, Agnes, Wolfe, Julia, Won, Minhee   +41 more
core   +2 more sources

Mechanisms of nuclear content loading to exosomes. [PDF]

, 2019
Exosome cargoes are highly varied and include proteins, small RNAs, and genomic DNA (gDNA). The presence of gDNA suggests that different intracellular compartments contribute to exosome loading, resulting in distinct exosome subpopulations.
Burks, Jared K, Clise-Dwyer, Karen, De Hoff, Peter, Laurent, Louise C, Liu, Jinsong, Morey, Robert, O'Halloran, Theresa J, Oliphint, Paul Allen, Roszik, Jason, Song, Xingzhi, Sood, Anil K, Villar-Prados, Alejandro, Yokoi, Akira, Zhang, Jianhua   +13 more
core  

Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life

Опухоли женской репродуктивной системы, 2014
The main goals of the study were to evaluate the efficacy and safety of intravenous topotecan (Hycamtin) used in a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day course of therapy in patients with recurrent ovarian cancer.
E. G. Novikova, I. A. Korneyeva, E. A. Ronina, S. A. Shcheltsyna, E. D. Pashanov   +4 more
doaj   +1 more source

Patent Disclosure and R&D Competition in Pharmaceuticals. [PDF]

The prominent role played by patents within the pharmaceutical domain is unquestionable. In this paper we take an unusual perspective and focus on a relatively neglected implication of patents: the effect of patent-induced information disclosure (of both
Fabio Pammolli, Laura Magazzini, Maria Alessandra Rossi, Massimo Riccaboni   +3 more
core   +3 more sources

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment

Diagnostics
Background: Small-cell lung cancer (SCLC) is a highly aggressive tumor, and overall survival (OS) remains poor despite intensive efforts to develop new treatment strategies.
Laura Lambrecht, Paola Arnold, Jürgen Behr, Pontus Mertsch, Amanda Tufman, Diego Kauffmann-Guerrero   +5 more
doaj   +1 more source

Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside

OncoImmunology, 2018
Despite recent advances in high-risk neuroblastoma therapy, the prognosis for patients remains poor. In addition, many patients suffer from complications related to available therapies that are highly detrimental to their quality of life.
S. Faraj, M. Bahri, S. Fougeray, A. El Roz, J. Fleurence, J. Véziers, M. D. Leclair, E. Thébaud, F. Paris, S. Birklé   +9 more
doaj   +1 more source

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. [PDF]

, 2017
Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic ...
Beckman, Robert A., Boca, Simina M., Brody, Jonathan R., Madhavan, Subha, Marshall, John L., Pishvaian, Michael J., Rao, Shruti, Riazi, Shahla, Yabar, Cinthya S.   +8 more
core   +1 more source

Patient derived xenograft models of small-cell lung cancer provide molecular insights into mechanisms of chemotherapy cross-resistance [PDF]

, 2018
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung cancer the median survival time of 14.5 months has seen little improvement over the last four ...
Myers, David Thomas
core  

Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2010
Background and objective How to prolong progression free survival (PFS) and overall survival (OS) of patients with small cell lung cancer (SCLC) has been one of the hottest issues. We retrospectively reviewed our data to compare the survival of immediate
Cong XUE, Yuanyuan ZHAO, Liping LIN, Guangchuan XU, Hongyun ZHAO, Yang ZHANG, Wei JIANG, Li ZHANG   +7 more
doaj  

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinumrefractory small cell lung cancer patients [PDF]

, 2017
Azab, Mohammad, Byers, Lauren Averett, Camidge, Daivd Ross, Cardnell, Robert J, Fujimoto, Junya, Ghandi, Jitendra, Horn, Leora, Kloecker, Goetz, Krzakowski, Maciej, Owonikoko, Taofeek, Taverna, Pietro, Waqar, Saiama Naheed   +11 more
core   +2 more sources